The role of orexin A in metabolic disturbances in patients with acromegaly

被引:0
作者
Jawiarczyk-Przybylowska, Aleksandra [1 ]
Bolanowski, Marek [1 ]
机构
[1] Wroclaw Med Univ, Dept Endocrinol Diabetol & Isotope Therapy, PL-50367 Wroclaw, Poland
关键词
acromegaly; orexin A; metabolic disturbances; GROWTH-HORMONE; INSULIN-RESISTANCE; BODY-COMPOSITION; IN-VITRO; LIPOPROTEIN; SECRETION; OCTREOTIDE; PEPTIDES;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: It has been reported that orexins may play an important role in GM regulation. Orexins participate in the regulation of pituitary hormones secretion, food intake regulation, and the sleep-wake cycle. It has been suggested that a defect of orexin A synthesis could be responsible for disturbances in GH synthesis in patients with acromegaly, and consequently aggravate metabolic disturbances caused by high levels of IGF1. The aim of this study: The aim of this study was to assess orexin A levels in relation to the activity of the disease and the influence on metabolic profile in patients with acromegaly. Material and methods: The subjects were 55 acromegalic patients divided into three main groups: a surgically cured acromegalic group (SCA); a well-controlled acromegalic group (WCA); an active acromegalic group (AA); and 29 healthy controls. In all subjects, blood samples were taken to assess the concentration of orexin A, lipids, glucose, insulin and hormones of the pituitary and peripheral glands. Results: The concentration of orexin A was highest in the control group (CG) and lowest in the WCA group. The differences of orexin A concentration were statistically significant when each group of acromegalics were compared to the CG. There were no significant differences in orexin A concentration among the studied groups of patients with acromegaly. The metabolic disturbances were more often observed in the groups of acromegaly patients. In the AA group, orexin A concentrations correlated negatively with plasma lipids. Conclusions: The concentration of orexin A is reduced in acromegaly compared to healthy subjects. (Endokrynol Pol 2012; 63 (6): 463-469)
引用
收藏
页码:463 / 469
页数:7
相关论文
共 34 条
  • [1] Mortality in 154 surgically treated patients with acromegaly - A 10-year follow-up survey
    Arita, K
    Kurisu, K
    Tominaga, A
    Eguchi, K
    Iida, K
    Uozumi, T
    Kasagi, F
    [J]. ENDOCRINE JOURNAL, 2003, 50 (02) : 163 - 172
  • [2] LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy
    Arosio, M
    Sartore, G
    Rossi, CM
    Casati, G
    Faglia, G
    Manzato, E
    [J]. ATHEROSCLEROSIS, 2000, 151 (02) : 551 - 557
  • [3] Baldys-Waligórska A, 2011, ENDOKRYNOL POL, V62, P401
  • [4] Baranowska B, 2005, NEUROENDOCRINOL LETT, V26, P293
  • [5] Bolanowski Marek, 2002, Med Sci Monit, V8, pCR685
  • [6] Castro GFM, 2000, CLIN ENDOCRINOL, V53, P313
  • [7] Acromegaly
    Chanson, Philippe
    Salenave, Sylvie
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2008, 3 (1)
  • [8] The in vitro regulation of growth hormone secretion by orexins
    Chen, C
    Xu, RW
    [J]. ENDOCRINE, 2003, 22 (01) : 57 - 66
  • [9] EFFECTS OF OCTREOTIDE ON LIPID-METABOLISM IN ACROMEGALY
    COHEN, R
    CHANSON, P
    BRUCKERT, E
    TIMSIT, J
    LEGRAND, A
    HARRIS, AG
    GUILLAUSSEAU, PJ
    WARNET, A
    LUBETZKI, J
    [J]. HORMONE AND METABOLIC RESEARCH, 1992, 24 (08) : 397 - 400
  • [10] Distribution of orexin/hypocretin in the rat median eminence and pituitary
    Date, Y
    Mondal, MS
    Matsukura, S
    Ueta, Y
    Yamashita, H
    Kaiya, H
    Kangawa, K
    Nakazato, M
    [J]. MOLECULAR BRAIN RESEARCH, 2000, 76 (01): : 1 - 6